Manufacturer
82 recalls in our database name Mylan Pharmaceuticals Inc. as the manufacturing or recalling firm.
Of the 82 recalls from Mylan Pharmaceuticals Inc. we have scored against our rubric, 2 (2%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 30 (37%) are Severe.
Which agencies issued them
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Mylan Pharmaceuticals is recalling Acamprosate Calcium tablets that failed to meet dissolution specifications.
Mylan Pharmaceuticals is recalling one lot of Mycophenolate Mofetil for Injection, 500 mg/vial, because precipitate was found in the vials. The recall covers 5,688 vials distributed nationwide.
Mylan Pharmaceuticals is recalling two lots of Amnesteem (Isotretinoin) Capsules 40 mg after the product failed dissolution specifications.
Mylan Pharmaceuticals is recalling specific lots of Prasugrel 5 mg tablets due to failed dissolution specifications. The affected tablets may not dissolve properly in the body.
Mylan Pharmaceuticals is recalling Insulin Glargine prefilled pens (lot BF21002895) distributed nationwide because some pens lack labels, which could prevent patients from properly identifying and administering the medication.
Mylan Pharmaceuticals is recalling 89,665 vials of Insulin Glargine Injection (100 units/mL) due to missing labels on the vials. Affected patients should not use the product and should contact their healthcare provider.
Mylan Pharmaceuticals is recalling injectable Rifampin vials nationwide due to failed impurities and degradation specifications discovered during stability testing.
Mylan Pharmaceuticals recalls one lot of Travoprost ophthalmic solution due to subpotency and impurity issues found during stability testing. Patients should consult their pharmacist or physician if they have medication from this lot.
Mylan Pharmaceuticals Inc is voluntarily recalling Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol due to current Good Manufacturing Practice (cGMP) deficiencies. The recall affects 233,199 10-gram aerosol containers distributed nationwide.
Mylan Pharmaceuticals is recalling approximately 73,175 Semglee (insulin glargine) prefilled pens nationwide because some units have a missing label. Patients should check their pens and contact their pharmacist or doctor if affected.
Mylan Pharmaceuticals is recalling specific lots of Candesartan Cilexetil and Hydrochlorothiazide tablets due to out-of-specification organic impurities found during routine stability testing.
Mylan Pharmaceuticals is recalling specific lots of 5mg Tacrolimus capsules because 1mg capsules may be present in the bottles.
Mylan Pharmaceuticals is recalling Sotalol HCL 80 mg tablets because of the presence of metal particles. The affected lot was distributed nationwide.
Mylan Pharmaceuticals is recalling Nizatidine Capsules 150 mg because trace amounts of the impurity NDMA were detected in the active ingredient.
Mylan Pharmaceuticals is recalling Nizatidine Capsules 300 mg because trace amounts of the impurity NDMA were detected in the active ingredient.
Mylan Pharmaceuticals is recalling Alprazolam 0.5 mg tablets because they contain a foreign substance. Consumers should stop using the affected lot and contact their pharmacist.
Mylan Pharmaceuticals is recalling 4,272 bottles of Prasugrel 5 mg tablets because they failed to meet dissolution specifications.
Mylan Pharmaceuticals is recalling Gatifloxacin Ophthalmic Solution 0.5% due to an out-of-specification result for an unknown impurity.
Mylan Pharmaceuticals is recalling Diltiazem HCl Extended-Release Capsules 180mg because routine stability testing found high out-of-specification impurities.
Mylan Pharmaceuticals is recalling DrNatura Flora Protect Probiotics and Toxinout Kits due to an undeclared soy allergen statement.
Mylan Pharmaceuticals is recalling DrNatura Flora Protect Probiotics because the product contains an undeclared soy allergen.
Mylan Pharmaceuticals is recalling 10,390 bottles of Dymista nasal spray because the glass bottles may have broken glass in the neck area.
Mylan Pharmaceuticals is recalling specific lots of Fexofenadine HCl 180 mg tablets because routine stability testing showed slightly elevated related compounds.
Mylan Pharmaceuticals is recalling Valsartan tablets because FDA testing found the impurity N-nitrosodiethylamine (NDEA). The affected product was distributed throughout the United States.
Mylan Pharmaceuticals is recalling specific lots of Valsartan and Hydrochlorothiazide tablets because FDA labs confirmed the presence of the impurity N-nitrosodiethylamine (NDEA).